Prosecution Insights
Last updated: November 20, 2026
Application No. 18/691,216

COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Mar 12, 2024
Priority
Sep 15, 2021 — EU 21196824.3 +1 more
Examiner
ZARA, JANE J
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Evonik Operations GmbH
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
788 granted / 1109 resolved
+11.1% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
49 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
5.4%
-34.6% vs TC avg
§103
30.6%
-9.4% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1109 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office action is in response to the communications filed 3-12-24 and 9-21-26. Claims 1-20 are pending in the instant application. Election/Restrictions Applicant's election with traverse of Group I, claims 1-8 and 16-19, in the reply filed on 9-21-26, is acknowledged. The traversal is on the ground(s) that the election of species is improper and the species should be rejoined. Upon further consideration, the species requirement is hereby withdrawn. The requirement between inventions is still deemed proper and is therefore made FINAL. Claims 9-15, and 20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 9-21-26. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-8 and 16-19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1, 2, 8, 16, 19 recite the term “molar ratio” to be “between 1000 and 20” (see, e.g., claim 16). It is unclear what ratio is being recited in the claims. A molar ratio is ​the ratio between the amounts, e.g., in moles, of any two compounds. Appropriate correction is required. In claims 1-6, 16-18, the terms “at least one dipeptide” and “at least one trace metal” are vague and indefinite. The metes and bounds cannot be determined. Appropriate correction is required. In claims 8 and 19, the term “from about “ is vague and indefinite. The metes and bounds cannot be determined. Appropriate correction is required. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-14 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The breadth of the claims: The claims are broadly drawn to compositions comprising at least one dipeptide consisting of two amino acids, said amino acids being natural amino acids and at least one comprising cysteine (Cys), and at least one trace metal ion, which trace metal optionally comprises iron, lithium, zinc, copper, chromium, nickel, cobalt, vanadium, molybdenum, or manganese, which dipeptide concentration is between 0.1 and 200 mM and which trace metal ion concentration is between 0.1 and 400 pM, and which dipeptide optionally comprises Xxx-Cys or Cys-Xxx, wherein Xxx is a natural amino acid, the dipeptide optionally comprising Ala- Cys, Cys-Ala, Lys-Cys ,and/or Cys-Lys, wherein at least one dipeptide is optionally Xxx-Cys or Cys-Xxx and is optionally in the oxidized and dimerized form, which compositions optionally further comprise free cysteine, which dipeptide concentration is between 0.5 and 10 mM and the trace metal ion concentration is between 0.5 and 20 pM, wherein the molar ratio of the dipeptide bound cysteine to the free cysteine is from about 0.5 to 2. Teachings in the specification The specification teaches the following: The addition of L-cysteine and Cu(II) at several concentrations to cell culture media resulted in a significant, concentration-depended reduction in cell viability (Figure 1 A and B). No toxic effect was observed replacing L-cysteine with an equimolar amount of the dipeptides (Ala-Cys)₂ and (Lys- Cys)₂. Instead, viability was even increased providing beneficial effects of combining dipeptides with Cu(II) (Figure 2 A and B, Figure 3 A and B). Toxicity at highest concentration tested was only observed with L-cysteine (Figure 4). Figure 1-A and 1-B shows the effects of Cu(II) and L-cysteine addition at different concentrations and ratios on the viability of MSCs and CHO cells, respectively. A strong increase in toxicity was observed with increasing concentrations of Cu as well as L-cysteine. Figure 2-A and 2-B shows the effects of Cu(II) and (Ala-Cys)₂ addition at different concentrations and ratios on the viability of MSCs and CHO cells, respectively. In contrast to Figure 1-A and 1-B, no toxic effects were observed. For selected combinations of (Ala-Cys)₂ and Cu(II), a pronounced positive effect on viability was observed. Figure 3-A and 3-B shows the effects of Cu(II) and (Ala-Cys)₂ addition at different concentrations and ratios on the viability of MSCs and CHO cells, respectively. In contrast to Figure 1-A and 1-B, no toxic effects were observed. For selected combinations of (Lys-Cys)₂ and Cu(II), a pronounced positive effect on viability was observed. Figure 4 shows control experiments depicting the effect of the addition of single components (L-cysteine, (Ala-Cys)₂, (Lys-Cys)₂, Cu(II)) at various concentrations on the viability of MSCs. Only L- cysteine negatively affected viability. Cu(II) up to 5 µM (MSCs) or 40 µM (CHO cells) did not have a negative effect on viability. [Emphases added] [Citations omitted]. The specification fails to provide the requisite guidance for making and using the broad genus of formulations instantly claimed. The examples fail to provide a representative number of species adequately describing the broad genus claimed. Since the disclosure fails to describe the common attributes and characteristics concisely identifying members of the proposed genus, and because the claimed genus is highly variant, the description provided is insufficient. One of skill in the art would reasonably conclude that the disclosure fails to provide a concise description of the broad genus of formulations instantly claimed. Thus, Applicant was not in possession of the broadly claimed genus. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-8 and 16-19 is/are rejected under 35 U.S.C. 103 as being unpatentable over Sanchez-Kopper et al (AMB Expr., Vol. 6, No. 48, pages 1-12 (2016)), Yu et al (US 2018/0135077), and Barrett et al (WO 2011/133902), the combination in view of Qian, Z. (CN 2015/10406329), Kenerson, R. W. (US 2005/0287666), and Graham et al (Applied Microbiology and Biotechnology, Vol. 104, pages 1097-1108 (2020)). The claims are drawn to compositions comprising at least one dipeptide consisting of two amino acids, said amino acids being natural amino acids and at least one comprising cysteine (Cys), and at least one trace metal ion, which trace metal optionally comprises iron, lithium, zinc, copper, chromium, nickel, cobalt, vanadium, molybdenum, or manganese, which dipeptide concentration is between 0.1 and 200 mM and which trace metal ion concentration is between 0.1 and 400 pM, and which dipeptide optionally comprises Xxx-Cys or Cys-Xxx, wherein Xxx is a natural amino acid, the dipeptide optionally comprising Ala- Cys, Cys-Ala, Lys-Cys ,and/or Cys-Lys, wherein at least one dipeptide is optionally Xxx-Cys or Cys-Xxx and is optionally in the oxidized and dimerized form, which compositions optionally further comprise free cysteine, which dipeptide concentration is between 0.5 and 10 mM and the trace metal ion concentration is between 0.5 and 20 pM, wherein the molar ratio of the dipeptide bound cysteine to the free cysteine is from about 0.5 to 2. Sanchez-Kopper et al (AMB Expr., Vol. 6, No. 48, pages 1-12 (2016)) teach dipeptides as important molecules in cell cultures for boosting cell productivity. Dipeptides include alanyl-cysteine (second full para, page 2), providing significant increases in intracellular alanine and cystine (bridging para, pages 8-9, Fig. 8 on page 9, Discussion, bridging par, pages 6-7). Yu et al (US 2018/0135077) teach cell culture compositions comprising dipeptides including Alanyl-Cysteine dimers (Table 1 on page 3, para 0090, claims 11, 13-14, 19). Barrett et al (WO 2011/133902) teach cell culture compositions comprising dipeptides comprising cysteine, including at concentrations of between 8.5-1 g/L (second full para on page 4; third full para, page 7; claims 1-4, 8, 15-17, 26-30, 37-39). The primary references do not teach the concentrations for both the dipeptide and the trace metal ions claimed. Keenan et al (In Vitro Cellular and Developmental Biology, Vol. 54, pages 555-558 (2018)) teach copper as an essential trace element micronutrient for nutrition. Keenan teaches levels of copper, iron, manganese and zinc in cell culture compositions (pages 556-558). Qian, Z. (CN 2015/10406329) teaches cell culture compositions comprising dipeptides between a concentration range of 0.5-3mM (page 2, claim 7). Qian teaches cell culture compositions comprising copper, zinc, selenium and/or cobalt at concentrations between .05 um -.1 M (page 2, claim 5). Kenerson, R. W. (US 2005/0287666) teach cell culture media comprising the concentration optimization of trace metals, optionally comprising zinc, copper and macromolecules including peptides (page 5, first full para, page 5; para 0027, 0030, 0046, 0048, 0050, 0064, 0065, 0075-0156, 0161-0186, Tables 1-3 on page 13, claims 1-21, 25, 45-48, 60-65). Graham et al (Applied Microbiology and Biotechnology, Vol. 104, pages 1097-1108 (2020)) (See IDS filed 5-1-24) teach the importance of trace metals in cell culture as affecting production and quality of translated proteins. Graham teaches the optimization of zinc and copper concentrations as supplements for cell cultures. Zn and copper concentrations were tested at e.g., 50uM (see esp. the Abstract, first two full paras on page 1098, bridging para pages 1098-1099, first full para on page 1099, Results, page 1100-1103, Fig. 6 on page 1105). It would have been obvious to provide the dipeptide and trace metal compositions claimed in culture media because the prior art disclosed the importance of these entities for bolstering cell culture and translated protein production, as illustrated in the teachings of Sanchez-Kopper, Yu and Barrett. In addition, one of ordinary skill in the art would have been motivated to provide the trace metals of copper and zinc for enhancing production and quality of translated proteins in cell cultures, as taught by Qian, Kenerson, and Graham. For these and the aforementioned reasons, the instant invention would have been obvious to one of ordinary skill in the art prior to the effective filing date of the instant invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-8 and 16-19 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of copending Application No. 18/698,415 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are drawn to compositions comprising at least one dipeptide consisting of two amino acids, said amino acids being natural amino acids and at least one of the said amino acids being cysteine (Cys), and at least one trace metal ion. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Certain papers related to this application may be submitted to Art Unit 1637 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. The examiner’s office hours are generally Monday-Friday, 10:30am - 7pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jennifer Dunston, can be reached on (571)-272-2916. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Jane Zara 11-10-26 /JANE J ZARA/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Mar 12, 2024
Application Filed
Mar 12, 2024
Response after Non-Final Action
Nov 13, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799147
RIBONUCLEIC ACID PURIFICATION
3y 6m to grant Granted Nov 17, 2026
Patent 12774468
DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES
3y 1m to grant Granted Oct 27, 2026
Patent 12735704
ANTICANCER ADJUVANT AND PHARMACEUTICAL COMPOSITION FOR TREATING ANTICANCER-AGENT-RESISTANT CANCER, AND KIT COMPRISING SAME
3y 11m to grant Granted Sep 15, 2026
Patent 12734251
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
3y 7m to grant Granted Sep 15, 2026
Patent 12703734
METHOD OF ASSESSING ACTIVITY OF RECOMBINANT ANTIGEN RECEPTORS
2y 9m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
87%
With Interview (+16.1%)
2y 11m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1109 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month